CoChat

Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction

Open access

The DOI matches its Crossref record; 84 of the 89 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) is the most common neurodegenerative disorder and results in severe neurodegeneration and progressive cognitive decline. Neurotrophins are growth factors involved in the development and survival of neurons, but also in underlying mechanisms for memory formation such as hippocampal long-term potentiation. Our aim was to identify small molecules with stimulatory effects on the signaling of two neurotrophins, the nerve growth factor (NGF) and the brain derived neurotrophic factor (BDNF). To identify molecules that could potentiate neurotrophin signaling, 25,000 molecules were screened, which led to the identification of the triazinetrione derivatives ACD855 (Ponazuril) and later on ACD856, as positive allosteric modulators of tropomyosin related kinase (Trk) receptors. ACD855 or ACD856 potentiated the cellular signaling of the neurotrophin receptors with EC50 values of 1.9 and 3.2 or 0.38 and 0.30 µM, respectively, for TrkA or TrkB. ACD855 increased acetylcholine levels in the hippocampus by 40% and facilitated long term potentiation in rat brain slices. The compounds acted as cognitive enhancers in a TrkB-dependent manner in several different behavioral models. Finally, the age-induced cognitive dysfunction in 18-month-old mice could be restored to the same level as found in 2-month-old mice after a single treatment of ACD856. We have identified a novel mechanism to modulate the activity of the Trk-receptors. The identification of the positive allosteric modulators of the Trk-receptors might have implications for the treatment of Alzheimer’s diseases and other diseases characterized by cognitive impairment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells10081871

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Chemical structure of (a) Toltrazuril and its oxidized analogues (b) Toltrazurilsulfoxide and (c) Toltrazurilsulfone.
Figure 1 Chemical structure of (a) Toltrazuril and its oxidized analogues (b) Toltrazurilsulfoxide and (c) Toltrazurilsulfone.CC BY · PubMed Central
Figure 2 In vitro effects of ACD855 on NGF- or BDNF-signaling. U2OS cells expressing TrkA or TrkB were used to determine the effects of ACD855 at different concentrations of NGF or BDNF or to determine the effects of ACD855 on the dose–response curve of NGF. U2OS-TrkA (a) or U2OS-TrkB (b) cells (5000 cells per well) were incubated with an increasing amount of ACD855 and a fixed concentration of NGF (a) or BDNF (b), as indicated (0 ng/mL (black lines and triangles), 1 ng/mL (red lines and circles), or 10 ng/mL (blue lines and squares). 100% was defined as the activity obtained with 30 ng NGF/mL. (c) U2OS-TrkA cells were incubated with DMSO or with 0.3, 1, or 3 µM of ACD855, as indicated in the absence or presence of increasing amounts of NGF to achieve complete dose–response curves of NGF. Luminescence units were the total amount of luminescence obtained at all wavelengths from each well. The amount of luminescence was a direct measurement of the amount of SHC-1 interacting with the phosphorylated tyrosine residue 490 of the TrkA and thus an indirect measurement of receptor activation.
Figure 2 In vitro effects of ACD855 on NGF- or BDNF-signaling. U2OS cells expressing TrkA or TrkB were used to determine the effects of ACD855 at different concentrations of NGF or BDNF or to determine the effects of ACD855 on the dose–response curve of NGF. U2OS-TrkA (a) or U2OS-TrkB (b) cells (5000 cells per well) were incubated with an increasing amount of ACD855 and a fixed concentration of NGF (a) or BDNF (b), as indicated (0 ng/mL (black lines and triangles), 1 ng/mL (red lines and circles), or 10 ng/mL (blue lines and squares). 100% was defined as the activity obtained with 30 ng NGF/mL. (c) U2OS-TrkA cells were incubated with DMSO or with 0.3, 1, or 3 µM of ACD855, as indicated in the absence or presence of increasing amounts of NGF to achieve complete dose–response curves of NGF. Luminescence units were the total amount of luminescence obtained at all wavelengths from each well. The amount of luminescence was a direct measurement of the amount of SHC-1 interacting with the phosphorylated tyrosine residue 490 of the TrkA and thus an indirect measurement of receptor activation.CC BY · PubMed Central
Figure 3 Mechanism of action of triazinetriones on TrkA. (a) Full-length TrkA with a HA-tag (TrkA-HA) fused to the C-terminus was purified through immunoprecipitation using anti-HA agarose beads. Purified TrkA-HA was incubated with DMSO (blue circles and hatched line), ACD855 (5 µM) (black triangles and solid line), or ACD856 (1 µM) (red squares and solid line) for approx. 5 min. Thereafter, ATP was added to yield the indicated concentration. Each data point is the mean ± SEM (n = 3). The solid lines are the curve-fit using the Michaelis–Menten equation used to calculate the apparent Vmax(app) and km(app), and the dotted lines are the 95% confidence band for each curve fit. (b–d) Affinity labeling and streptavidin adsorption of Trka. (b) Western blot of streptavidin adsorbed TrkA-HA non-covalent labeled with NHS-biotinylated triazinetrione compound (lane 2) or covalent labeled by UV-crosslinking of 100 µM sulfo-SBED biotinylated compound (lane 3). Detection of immunoreactive band was performed with anti-TrkA antibody. Supernatant loaded to the left (lane 1) was used as positive control for the Western blot. Arrows on the left indicate the migration of molecular weight markers corresponding to 198, 98, and 62 kDa. (c) Anti-HA agarose immunoprecipitation of cross-linked or non-crosslinked sulfo-SBED compound (AC27019-SBED) from cell lysate incubated with 100 µM AC27019-SBED. Lane 1, non-UV-crosslinking, and lane 2, UV-crosslinking of sulfo-SBED labeled TrkA-HA, both detected with streptavidin-HRP. Lanes 3 and 4 are loading controls of lanes 1 and 2, respectively, were TrkA-HA was detected by immunoblotting using the anti-TrkA antibody. Both blots were part of the same gel, but the membrane was cut in two pieces, and the proteins were detected by streptavidin-HRP (left panel) or by an anti-TrkA antibody (right panel). (d) Streptavidin adsorption of biotinylated compound bound to TrkA-HA. Lane 1, cell lysate used for positive control of immunodetection; lane 3, cell lysate without biotinylated compound was adsorbed to streptavidin-agarose as negative control; lanes 5 and 7, cell lysates containing sulfo-SBED compound UV-crosslinked to TrkA (from two different experiments) were adsorbed to streptavidin-agarose and immunoblotted using anti-TrkA antibody. Lanes 2, 4, and 6 are empty lanes to avoid cross-contamination between lanes.
Figure 3 Mechanism of action of triazinetriones on TrkA. (a) Full-length TrkA with a HA-tag (TrkA-HA) fused to the C-terminus was purified through immunoprecipitation using anti-HA agarose beads. Purified TrkA-HA was incubated with DMSO (blue circles and hatched line), ACD855 (5 µM) (black triangles and solid line), or ACD856 (1 µM) (red squares and solid line) for approx. 5 min. Thereafter, ATP was added to yield the indicated concentration. Each data point is the mean ± SEM (n = 3). The solid lines are the curve-fit using the Michaelis–Menten equation used to calculate the apparent Vmax(app) and km(app), and the dotted lines are the 95% confidence band for each curve fit. (b–d) Affinity labeling and streptavidin adsorption of Trka. (b) Western blot of streptavidin adsorbed TrkA-HA non-covalent labeled with NHS-biotinylated triazinetrione compound (lane 2) or covalent labeled by UV-crosslinking of 100 µM sulfo-SBED biotinylated compound (lane 3). Detection of immunoreactive band was performed with anti-TrkA antibody. Supernatant loaded to the left (lane 1) was used as positive control for the Western blot. Arrows on the left indicate the migration of molecular weight markers corresponding to 198, 98, and 62 kDa. (c) Anti-HA agarose immunoprecipitation of cross-linked or non-crosslinked sulfo-SBED compound (AC27019-SBED) from cell lysate incubated with 100 µM AC27019-SBED. Lane 1, non-UV-crosslinking, and lane 2, UV-crosslinking of sulfo-SBED labeled TrkA-HA, both detected with streptavidin-HRP. Lanes 3 and 4 are loading controls of lanes 1 and 2, respectively, were TrkA-HA was detected by immunoblotting using the anti-TrkA antibody. Both blots were part of the same gel, but the membrane was cut in two pieces, and the proteins were detected by streptavidin-HRP (left panel) or by an anti-TrkA antibody (right panel). (d) Streptavidin adsorption of biotinylated compound bound to TrkA-HA. Lane 1, cell lysate used for positive control of immunodetection; lane 3, cell lysate without biotinylated compound was adsorbed to streptavidin-agarose as negative control; lanes 5 and 7, cell lysates containing sulfo-SBED compound UV-crosslinked to TrkA (from two different experiments) were adsorbed to streptavidin-agarose and immunoblotted using anti-TrkA antibody. Lanes 2, 4, and 6 are empty lanes to avoid cross-contamination between lanes.CC BY · PubMed Central
Figure 4 BDNF and ACD855 facilitates LTP induction in hippocampal rat slices. (a) Fifteen minutes after the addition of 50 ng/mL BDNF or 20 µM ACD855 to the perfusion media (aCSF), a subthreshold Ø burst stimulation (arrow) was delivered to the Schaffer collaterals. BDNF and ACD855 were washed out 15 min later, and fEPSP were monitored for 60 min after the stimulation. (b) Evoked synaptic responses remained potentiated for 60 min after the Ø burst stimulation in slices perfused with 50 ng/mL BDNF (blue circles, n = 9 slices from 7 rats) or 20 µM ACD855 (red circles; n = 7 slices from 5 rats) when compared to control slices (black circles, n = 9 slices from 9 rats). Data are expressed as mean ± SEM. * p < 0.05 vs. control and ** p < 0.01 vs. control.
Figure 4 BDNF and ACD855 facilitates LTP induction in hippocampal rat slices. (a) Fifteen minutes after the addition of 50 ng/mL BDNF or 20 µM ACD855 to the perfusion media (aCSF), a subthreshold Ø burst stimulation (arrow) was delivered to the Schaffer collaterals. BDNF and ACD855 were washed out 15 min later, and fEPSP were monitored for 60 min after the stimulation. (b) Evoked synaptic responses remained potentiated for 60 min after the Ø burst stimulation in slices perfused with 50 ng/mL BDNF (blue circles, n = 9 slices from 7 rats) or 20 µM ACD855 (red circles; n = 7 slices from 5 rats) when compared to control slices (black circles, n = 9 slices from 9 rats). Data are expressed as mean ± SEM. * p < 0.05 vs. control and ** p < 0.01 vs. control.CC BY · PubMed Central
Figure 5 Effects of ACD855 in the Morris water maze. Subsequent to the pretraining, four days of spatial training in the water maze took place, whereby the animals received four daily trials starting at four different starting points around the water tank. Time to locate the platform (latency) was measured. Vehicle-treated animals (red line and circle) learned the task rapidly, while scopolamine- (0.3 mg/kg) treated animals (blue line and squares) had a highly significant impairment in swim latency, (* p < 0.05 (Day 2) and ** p < 0.01 (Day 4); respectively) in comparison to the control group. ACD855 (3 mg/kg) completely blocked the impairing effect of scopolamine on swim latency (black line and diamonds) (# p < 0.05 (Day 3)). ACD855 on its own improved cognitive function compared to vehicle, as there was rapid learning exhibited on Day 1 that significantly differed from the control animals (green line and triangles) (* p < 0.05 (Day 1)).
Figure 5 Effects of ACD855 in the Morris water maze. Subsequent to the pretraining, four days of spatial training in the water maze took place, whereby the animals received four daily trials starting at four different starting points around the water tank. Time to locate the platform (latency) was measured. Vehicle-treated animals (red line and circle) learned the task rapidly, while scopolamine- (0.3 mg/kg) treated animals (blue line and squares) had a highly significant impairment in swim latency, (* p < 0.05 (Day 2) and ** p < 0.01 (Day 4); respectively) in comparison to the control group. ACD855 (3 mg/kg) completely blocked the impairing effect of scopolamine on swim latency (black line and diamonds) (# p < 0.05 (Day 3)). ACD855 on its own improved cognitive function compared to vehicle, as there was rapid learning exhibited on Day 1 that significantly differed from the control animals (green line and triangles) (* p < 0.05 (Day 1)).CC BY · PubMed Central
Figure 6 ACD855 or ACD856 reverses memory-impairment in the passive avoidance task in mice. ACD855 (3 or 10 mg/kg) was administered s.c. for 4 consecutive days, whereas ACD856 (0.1, 0.3 or 1 mg/kg) was administered as a single dose 60 min prior to the experiment in combination with scopolamine (0.3 mg/kg, s.c.), MK-801 (0.3 mg/kg, i.p.), ANA-12 (0.5 mg/kg, s.c), or physostigmine (0.0125 mg/kg, s.c). Memory was assessed by measuring the total time the animals spent in the bright compartment, the maximum being 300 s. (a,b) ACD855 or ACD856 reversed scopolamine-induced memory impairment at the indicated doses. ** p < 0.01 or **** p < 0.0001 for scopolamine vs. the control group. #### p < 0.0001, ## p < 0.01, or # p < 0.05 for compound and scopolamine-treated animals vs. the scopolamine-treated group. (c,d) ACD855 or ACD856 reversed MK-801 induced memory impairment at the indicated doses. **** p < 0.0001 for MK-801 vs. the control group. ### p < 0.001 or ## p < 0.01 for compound- and MK-801-treated animals vs. the MK-801-treated group. (e,f) ANA12 inhibited ACD855- or ACD856-induced memory improvement. Animals were treated with scopolamine, ACD855 or ACD856 or ANA-12 as indicated (mg/kg). **** p < 0.001 for scopolamine vs. the control group. ## p < 0.01 for ACD855- and scopolamine-treated animals vs. the scopolamine-treated group, & p < 0.05 or && p < 0.01 for 855 and scopolamine- treated animals vs. ANA-12-, ACD855-, and scopolamine-treated group. (g,h) Physostigmine and ACD855 or ACD856 acted in an additive manner to reverse scopolamine-induced impairment. **** p < 0.0001 for scopolamine vs. the control group. **** p < 0.0001 or ** p < 0.01 for scopolamine + physostigmine vs. the control group. *** p < 0.001 or ** p < 0.01 for scopolamine + ACD855 or ACD856 vs. the control group and ### p < 0.001 or # p < 0.05 for scopolamine-, ACD856-, and physostigmine-treated animals vs. the scopolamine-treated group.
Figure 6 ACD855 or ACD856 reverses memory-impairment in the passive avoidance task in mice. ACD855 (3 or 10 mg/kg) was administered s.c. for 4 consecutive days, whereas ACD856 (0.1, 0.3 or 1 mg/kg) was administered as a single dose 60 min prior to the experiment in combination with scopolamine (0.3 mg/kg, s.c.), MK-801 (0.3 mg/kg, i.p.), ANA-12 (0.5 mg/kg, s.c), or physostigmine (0.0125 mg/kg, s.c). Memory was assessed by measuring the total time the animals spent in the bright compartment, the maximum being 300 s. (a,b) ACD855 or ACD856 reversed scopolamine-induced memory impairment at the indicated doses. ** p < 0.01 or **** p < 0.0001 for scopolamine vs. the control group. #### p < 0.0001, ## p < 0.01, or # p < 0.05 for compound and scopolamine-treated animals vs. the scopolamine-treated group. (c,d) ACD855 or ACD856 reversed MK-801 induced memory impairment at the indicated doses. **** p < 0.0001 for MK-801 vs. the control group. ### p < 0.001 or ## p < 0.01 for compound- and MK-801-treated animals vs. the MK-801-treated group. (e,f) ANA12 inhibited ACD855- or ACD856-induced memory improvement. Animals were treated with scopolamine, ACD855 or ACD856 or ANA-12 as indicated (mg/kg). **** p < 0.001 for scopolamine vs. the control group. ## p < 0.01 for ACD855- and scopolamine-treated animals vs. the scopolamine-treated group, & p < 0.05 or && p < 0.01 for 855 and scopolamine- treated animals vs. ANA-12-, ACD855-, and scopolamine-treated group. (g,h) Physostigmine and ACD855 or ACD856 acted in an additive manner to reverse scopolamine-induced impairment. **** p < 0.0001 for scopolamine vs. the control group. **** p < 0.0001 or ** p < 0.01 for scopolamine + physostigmine vs. the control group. *** p < 0.001 or ** p < 0.01 for scopolamine + ACD855 or ACD856 vs. the control group and ### p < 0.001 or # p < 0.05 for scopolamine-, ACD856-, and physostigmine-treated animals vs. the scopolamine-treated group.CC BY · PubMed Central
Figure 7 Effects of ACD855 and donepezil on object recognition in Wistar rats. ACD855 was administered for 4 consecutive days using 1 mg/kg, whereas donepezil was administered 30 min before the trial, both in combination with 1 mg/kg scopolamine. Groups treated with scopolamine and donepezil or ACD855 spent significantly greater time with the novel object. Black bars indicate familiar object and grey bars indicate novel object. ** p < 0.01 or * p < 0.05 for time spent on novel objects vs time spen on familiar objects.
Figure 7 Effects of ACD855 and donepezil on object recognition in Wistar rats. ACD855 was administered for 4 consecutive days using 1 mg/kg, whereas donepezil was administered 30 min before the trial, both in combination with 1 mg/kg scopolamine. Groups treated with scopolamine and donepezil or ACD855 spent significantly greater time with the novel object. Black bars indicate familiar object and grey bars indicate novel object. ** p < 0.01 or * p < 0.05 for time spent on novel objects vs time spen on familiar objects.CC BY · PubMed Central
Figure 8 ACD856 improves the acquisition, consolidation, and retrieval of memories. (a) Effects of ACD856 on acquisition, consolidation, or retrieval on scopolamine-induced amnesia in the passive avoidance model. The memory was assessed by measuring the total time that the animals spent in the bright compartment, the maximum being 300 s. Vehicle or ACD856 were administered as a single dose by subcutaneous (s.c.) injection (4 mL/kg body weight) at different timepoints in relation to the training session. On the day of training (Day 1), ACD856 or vehicle was administered either 60 min prior to training (pre-training, left graph) or 5 min post-training (post-training, middle graph). When evaluating the effects on the retrieval of memories on day 2, either vehicle or ACD856 was administered 30 min before the test session (pre-test). On the day of training, scopolamine at 0.3 mg/kg, or vehicle was administered subcutaneously 30 min prior to training. ** p < 0.01 or **** p < 0.0001 for scopolamine- vs. the vehicle-treated group (black bars). # p < 0.05 for compound and scopolamine-treated animals vs. the scopolamine-treated group. (b) ACD856 reversed aged-induced memory impairment at 24-h and 11 days post-dose. Left panel, the old mice displayed lower retention latency than the young mice, but it was not statistically significant. A single injection of ACD856 at a dose of 3 mg/kg induced a slight increase in retention latency in comparison to vehicle-treated old mice. Right panel, the retention latency was significantly higher in control young mice and the ACD856-treated group with old animals in comparison to the old control group when tested 11 days after the first retention test (* p < 0.05).
Figure 8 ACD856 improves the acquisition, consolidation, and retrieval of memories. (a) Effects of ACD856 on acquisition, consolidation, or retrieval on scopolamine-induced amnesia in the passive avoidance model. The memory was assessed by measuring the total time that the animals spent in the bright compartment, the maximum being 300 s. Vehicle or ACD856 were administered as a single dose by subcutaneous (s.c.) injection (4 mL/kg body weight) at different timepoints in relation to the training session. On the day of training (Day 1), ACD856 or vehicle was administered either 60 min prior to training (pre-training, left graph) or 5 min post-training (post-training, middle graph). When evaluating the effects on the retrieval of memories on day 2, either vehicle or ACD856 was administered 30 min before the test session (pre-test). On the day of training, scopolamine at 0.3 mg/kg, or vehicle was administered subcutaneously 30 min prior to training. ** p < 0.01 or **** p < 0.0001 for scopolamine- vs. the vehicle-treated group (black bars). # p < 0.05 for compound and scopolamine-treated animals vs. the scopolamine-treated group. (b) ACD856 reversed aged-induced memory impairment at 24-h and 11 days post-dose. Left panel, the old mice displayed lower retention latency than the young mice, but it was not statistically significant. A single injection of ACD856 at a dose of 3 mg/kg induced a slight increase in retention latency in comparison to vehicle-treated old mice. Right panel, the retention latency was significantly higher in control young mice and the ACD856-treated group with old animals in comparison to the old control group when tested 11 days after the first retention test (* p < 0.05).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 84 references

Cited by

See all 33

Metadata

Authors
Dahlström, M., Madjid, N., Nordvall, G., Halldin, M. M., Vazquez-Juarez, E., Lindskog, M., Sandin, J., Winblad, B., Eriksdotter, M., & Forsell, P.
Affiliations
  • Karolinska Institutet (SE)
  • AlzeCure Pharma (Sweden) (SE)
  • Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 171 77 Solna, Sweden
  • Karolinska University Hospital (SE)
Corresponding author
Forsell, Pontus
Venue
Cells
Publisher
MDPI AG
Published
2021-07-23
Volume
10
Issue
8
Pages
1871
ISSN
2073-4409 (ISSN-L)
OpenAlex
W3184010507
Cited by
33
References
89
Citations by year
2026: 7 · 2025: 7 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 4
FWCI
2.98
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Alzheimer's Drug Discovery Foundation (20151003)
  • VINNOVA (2014-00347)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
positive allosteric modulators, neurotrophin receptors, Trk receptors, TrkB, TrkA, nerve growth factor, brain-derived neurotrophic factor, Alzheimer's disease, cognitive impairment, nootropic drugs, long-term potentiation, acetylcholine, small molecule screening
MeSH terms
Age Factors, Animals, Behavior, Animal, Brain, Cognition, Disease Models, Animal, Humans, Male, Membrane Glycoproteins, Mice, Inbred C57BL, Motor Activity, Protein-Tyrosine Kinases, Triazines, Signal Transduction, Rats, Sprague-Dawley, Receptors, Nerve Growth Factor, Nootropic Agents, Maze Learning, Receptor, trkB, Receptor, trkA, Cell Line, Tumor, Mice, Rats, Small Molecule Libraries, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction. https://app.cochat.ai/papers/10.3390/cells10081871
The paper
Dahlström, M., Madjid, N., Nordvall, G., Halldin, M. M., Vazquez-Juarez, E., Lindskog, M., Sandin, J., Winblad, B., Eriksdotter, M., & Forsell, P. (2021). Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction. Cells. https://doi.org/10.3390/cells10081871

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.